In spite of recent advances in functional magnetic resonance imaging, the Wada test is still an important test for presurgical evaluation of patients with epilepsy. 2 The intracarotid sodium amytal test (Wada test) has been used to lateralize cerebral dominance for speech and to evaluate memory in each hemisphere. 3 Anesthesiologists are generally not involved in this procedure. In some centers, an anesthesiologist is on stand-by during the procedure to manage potential complications, namely stroke.
Intracarotid Etomidate
To the Editor:-We read with great interest the review by Dr. Joshi et al. on intracarotid delivery of drugs. 1 In spite of recent advances in functional magnetic resonance imaging, the Wada test is still an important test for presurgical evaluation of patients with epilepsy. 2 The intracarotid sodium amytal test (Wada test) has been used to lateralize cerebral dominance for speech and to evaluate memory in each hemisphere. 3 Anesthesiologists are generally not involved in this procedure. In some centers, an anesthesiologist is on stand-by during the procedure to manage potential complications, namely stroke.
In the article by Dr. Joshi et al., there is mention that baseline sedation provided by the anesthesiologist in attendance would further complicate the interpretation of the Wada test and also suggests use of a judicious amount of sedation during the procedure. We disagree with the suggestion by the authors for the use of sedation during the procedure. These tests are done for evaluation of memory and language with unilateral intracarotid injection of drugs. Any sedation during the procedure will interfere with the memory testing. 4 As a result of the recurrent shortages in the availability of sodium amytal, other agents are being used for Wada testing. As mentioned in the article, propofol or methohexitone have been used with limited success. 5 Jones-Gotman et al. have published their work in the use of etomidate for the Wada test. 6 They have shown that etomidate is a viable alternative to sodium amytal, and its administration by bolus followed by infusion offers an improvement over the traditional Wada test. It is given as a 2-mg initial bolus (0.03-0.04 mg/kg) over 30 to 60 s, then an infusion of 0.003 to 0.004 mg/kg/min (approximately 6 ml/h neat etomidate 2 mg/ml) until the speech assessment and memory objects have been introduced. Many centers in the world are now switching to this etomidate speech and memory test. Manufacturer's recommendations mandate an anesthesiologist to administer etomi-date, so many anesthesiologists are now involved. 7 In our institution, we have been using etomidate for the Wada test for the past year with great success. In addition, bilateral injection is our standard practice. The second injection is made only after the confirmation of complete clearance of the drug effects (both clinically and electroencephalographically). In Reply:-We thank Dr. Venkatraghavan for raising two specific comments on our review: The first is the use of sedation during Wada testing; the second is the use of intraarterial etomidate for the same procedure. 1 Both comments reinforce our general theme that there are significant variations in handling of anesthesia and interventional drugs, selection, and doses during endovascular procedures.
With regard to the "judicious use of sedation during Wada testing," Dr. Venkatraghavan correctly point out that Wada testing often is done without an anesthesiologist's supervision with minimal or no sedation. However, the anesthesiologists are routinely involved when any intervention is contemplated, such as during superselective Wada testing. For these longer procedures we use small doses of midazolam (1-2 mg), propofol (10 -25 g ⅐ kg Ϫ1 ⅐ min Ϫ1 ) and fentanyl 0.5-1.5 g/kg). These drugs are withheld at least 20 min before memory or psychomotor testing. Dundee and Wilson tested for anterograde amnesic action of midazolam (5 mg) and found the onset to be within 3 to 5 min, with the effect lasting 20 min. 2 Bulach et al. looked at midazolam pretreatment in a dose range of 2 to 10 mg and found a dose-dependent impairment of anterograde memory, but no effect on retrograde amnesia. 3 To our best knowledge there is no hard evidence to suggest that 1 to 2 mg of midazolam given 20 to 60 min before testing impairs conventional memory tests.
The question arises whether studies in healthy subjects apply to those with preexisting neurologic deficits. Low doses of residual sedative/hypnotics are known to unmask neurologic deficits and could in theory impair memory tests. 4 Hence, even if data from healthy volunteers might suggest a lack of amnesic effect with low doses of midazolam, caution needs to be exercised in prescribing sedatives or hypnotics to those with suspected neurologic deficits. What helped in framing the policies at our institution was a quality improvement review of patient data to assess the use of midazolam during Wada testing that found no impairment of memory.
We are thankful to Dr. Venkatraghavan for elaborating on the use of etomidate for Wada testing that is also supported by our experimental data. 5 These comments illustrate the diversity in the selection and dose of drugs used intraarterially or systemically during endovascular procedures. We emphasize that the surgeons and anesthesiologists should formulate a coherent management strategy based on the specific needs of the patient and endovascular procedure.
